[en] The long-term effect of intermittent low-dose nasal salmon calcitonin on trabecular early postmenopausal bone loss was assessed as follow-up to a previously published study. Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism. The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin. A total of 186 women complied with the study protocol throughout. The main outcome measures were bone mineral density of the lumbar spine (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine, and hydroxyproline/creatinine ratio). The average changes in bone mineral density after 36 months showed a positive (p < 0.05) outcome (1.8 +/- 5.7%; mean +/- SD) in the group treated with salmon calcitonin and calcium and a significant (p < 0.01) loss (-5.8 +/- 4.8%) in patients receiving calcium alone. The difference between the evolution of the two groups was significantly (p < 0.01) different after 6 months of treatment and remained so until the end of the study. No significant changes were recorded in biochemical parameters reflecting bone turnover. As previously shown during a 1 year follow-up, nasal salmon calcitonin given at low dose and intermittently, in association with calcium, can counteract trabecular postmenopausal bone loss.
Disciplines :
Rheumatology
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Denis, D.
Deroisy, Rita ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Lecart, M. P.
De Longueville, M.
Zegels, Brigitte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Sarlet, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Noirfalisse, P.
Franchimont, P.
Language :
English
Title :
Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin
Publication date :
January 1994
Journal title :
Journal of Bone and Mineral Research
ISSN :
0884-0431
eISSN :
1523-4681
Publisher :
Wiley-Blackwell, Washington, United States - District of Columbia
Christiansen C, Lindsay R (1991) Estrogens, bone loss and preservation. Osteoporosis Int 1:7-14.
Elstein AS, Holzman GB, Ravitch MM, Metheny WA, Holmes MM, Hoppe RB, Rothert ML, Rovner DR (1986) Comparison of physician's decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model. Am J Med 80:246-258.
Grisso JA, Baum CR, Turner BJ (1990) What do physicians in practice do to prevent osteoporosis?. J Bone Miner Res 5:213-258.
Eddy DM, Johnston CC, Lindsay R, Melton LJ (1989) Clinical indications for bone mass measurements. Report of the Scientific Advisory Committee of the National Osteoporosis Foundation. J Bone Miner Res 4S2:1-28.
Johnston CC, Melton LJ (1990) Guidelines for osteoporosis prophylaxis. Journal of Bone and Mineral Research 5:423-424.
(1991) More than hot flushes.2:917-918.
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) 1‐Year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481-1483.
Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of calcitonin given intranasally on early postmenopausal bone loss. BMJ 299:477-479.
Meunier PJ, Delmas PD, Chaumet‐Riffaud PD, Gozzo I, Duboeuf F, Chapuy MC, Guignard M (1990) Intranasal salmon calcitonin for prevention of postmenopausal bone loss. A placebo‐controlled study in 109 women. Osteoporosis 1990 , Christiansen C, Overgaard K, Osteopress, Copenhagen; 1861-1867.
MacIntyre L, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet 1:900-902.
Bray GA (1978) Definition, measurement and classification of the syndromes of obesity. Int J Obes 2:99-112.
Frumar AM, Meldrum DR, Geola F, Shamonki IM, Tataryn IV, Deftos LJ, Judd HL (1980) Relationship of fasting urinary calcium to circulating estrogen and body weight in postmenopausal women. J Clin Endocrinol Metab 50:70-75.
Reginster JY, Deroisy R, Sarlet N, Franchimont P (1990) Relationship between calcium intake during different periods of life and bone mineral content at the menopause. Osteoporosis 1990 , Christiansen C, Overgaard K, Osteopress ApS, Copenhagen; 400-401.
Krolner B, Porsnielsen S, Lund B, Lund BJ, Sorensen OH, Uhrenhold A (1980) Measurement of bone mineral content (BMC) of the lumbar spine. II. Correlation between forearm BMC and lumbar spine BMC. Scandinavian Journal of Clinical and Laboratory Investigation 40:665-670.
Reginster JY, Guesens P, Nijs J, Denis D, Franchimont P, Dequeker J (1989) In vivo long‐term precision of spinal bone mass measurement by dual photon absorptiometry. Bone Miner 6:225-229.
Trayser KA, Seligson D (1969) A new kinetic method for enzyme analysis suitable for automation. Clin Chem 15:452-459.
Nordin BEC (1978) Diagnostic procedure in disorders of calcium metabolism. Clin Endocrinol (Oxf) 8:55-67.
Zerbe GO (1979) Randomization analysis of the completely randomized design extended to growth and response curves. Journal of the American Statistical Association 74:215-221.
Reginster JY, Denis D, Deroisy R, Albert A, Sarlet N, Collette J, Franchimont P (1990) Dual photon absorptiometry of lumbar spine in Western European (Belgian) postmenopausal females: Normal range and fracture threshold. Clin Rheumatol 9:220-224.
Murlin JR, Gibb CBF, Romansky MJ, Steinhausen TB, Truax FL (1940) Effectiveness of perioral insulin in human diabetes. Am J Physiol 120:709-722.
Fink G, Gennser G, Liedholn P, Thoreil J (1974) Comparison of plasma levels of LH‐RH in men after intravenous and intranasal administration. J Endocrinol 63:351-360.
Pontiroli AE, Alberetto M, Secchi A, Dossi G, Bosi I, Pozza G (1982) Insulin given intranasally induces hypocalcaemia in normal and diabetic subjects. BMJ 284:303-306.
Pontiroli AE, Alberetto M, Pozza G (1983) Intranasal glucagon in healthy volunteers. BMJ 287:462-463.
Reginster JY, Denis D, Albert A, Franchimont P (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner 2:133-140.
Reginster JY, Albert A, Franchimont P (1985) Salmon calcitonin nasal spray in Paget's disease of bone; preliminary results in five patients. Calcif Tissue Int 37:577-580.
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen J (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 30:435-442.
Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired resistance. Arthritis Rheum 23:1148-1153.
de Deuxchaisnes, Devogelaer JP, Huaux JP, Dufour JP, Esselinckx W, Englebeen JP, Stasse P, Hermans P, de Buisseret JP (1987) New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop 217:56-71.
Reginster JY, Jeugmans‐Huynen AM, Albert A, Denis D, Franchimont P (1988) One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 3:249-252.
Bouizar Z, Rostene WH, Milhaud G (1987) Down‐regulation of rat kidney calcitonin receptors by salmon calcitonin infusion evidenced by autoradiography. Proc Natl Acad Sci USA 84:5125-5128.
Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C (1991) Dose‐resposne bioactivity of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344-349.
Kurose H, Seino Y, Shima M, Tanaka H, Ishida M, Yamaoka K, Yabuuchi H (1987) Intranasal absorption of salmon calcitonin. Calcif Tissue Int 41:249-251.
Reginster JY, Deroisy R, Albert A, Denis D, Lecart MP, Franchimont P (1989) Relationship between whole plasma calcitonin levels, calcitonin secretory capacity and plasma levels of estrone in healthy women and postmenopausal osteoporosis. J Clin Invest 83:1073-1077.
Guttmann S (1981) Chemistry and structure‐activity relationship of natural and synthetic calcitonin. Calcitonin 1980; Chemistry, Physiology, Pharmacology and Clinical Aspects , Pecile A, Exerpta Medica, Amsterdam; 11-24.
Tashjian AH, Wright DR, Ivey JL, Pont A (1978) Calcitonin binding sites in bone: Relationships to biological response and “escape.”. Recent Prog Horm Res 34:285-334.
Reginster JY, Franchimont P (1985) Side‐effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 3:155-157.
Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 2:1469-1471.